Related Experiment Video

Updated: Aug 26, 2026

MEDUSA for Identifying Death Regulatory Genes in Chemo-genetic Profiling Data
07:17

MEDUSA for Identifying Death Regulatory Genes in Chemo-genetic Profiling Data

Published on: February 7, 2025

Chemotherapy induces death receptor 5 in epithelial ovarian carcinoma

H J G Arts1, S de Jong, H Hollema

  • 1Department of Gynecological Oncology, University Hospital, Groningen, The Netherlands.

Gynecologic Oncology
|February 27, 2004
PubMed
Abstract

Insights

Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and its receptors are present in ovarian tumors. TRAIL may be a viable treatment option, especially for residual tumors after chemotherapy, as DR5 expression increases.

Area of Science:

  • Oncology
  • Molecular Biology
  • Apoptosis Research

Background:

  • Drug resistance often stems from defects in the apoptotic pathway.
  • Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) combined with chemotherapy effectively induces apoptosis in ovarian cancer cells in vitro.
  • Systemic TRAIL administration is a potential therapeutic strategy due to observed lack of toxicity in nonhuman primates.

Purpose of the Study:

  • To investigate the expression of TRAIL, its death receptors (DR4, DR5), and decoy receptor (DcR1) in normal ovaries and ovarian tumors.
  • To analyze TRAIL and receptor expression before and after chemotherapy in ovarian cancer.
  • To evaluate the therapeutic potential of TRAIL in ovarian cancer treatment.

Main Methods:

  • Immunohistochemical analysis of DR4, DR5, DcR1, and TRAIL expression.
  • Study included 5 normal ovaries, 15 early-stage (I/II), and 26 advanced-stage (III/IV) primary ovarian cancers.
  • Analysis of 19 paired tumor samples (pre- and post-chemotherapy) was performed.

Main Results:

  • Normal ovarian surface epithelium expressed TRAIL and its receptors; stromal cells expressed DcR1.
  • Ovarian cancers showed high expression of death receptors: 73% for DR4 and 51% for DR5.
  • TRAIL expression was lower in advanced-stage tumors (P<0.05), while DR5 expression was significantly higher in residual tumors post-chemotherapy (P=0.05).

Conclusions:

  • Early-stage ovarian tumors exhibit higher TRAIL expression compared to advanced stages.
  • The majority of primary and residual ovarian tumors express at least one TRAIL death receptor.
  • Increased DR5 expression in residual tumors suggests TRAIL could be a promising therapeutic agent for ovarian cancer.

More Related Videos

Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence08:55

Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence

Published on: November 2, 2014

Tropomodulin 3 Overexpression as a Marker for Platinum Resistance and Immune Infiltration in Ovarian Cancer09:40

Tropomodulin 3 Overexpression as a Marker for Platinum Resistance and Immune Infiltration in Ovarian Cancer

Published on: August 2, 2024

Related Concept Videos

Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
The Extrinsic Apoptotic Pathway01:17

The Extrinsic Apoptotic Pathway

The extrinsic apoptotic pathway is initiated when extracellular death-inducing signals, such as specific cytokines, activate the death receptors expressed on the cell surface. The immune cells involved in this pathway are natural killer cells (NK cells) and cytotoxic T-lymphocytes. NK cells are critical in innate immune response, while cytotoxic T-lymphocytes are associated with adaptive immune response. These cells recognize specific receptors expressed on the altered cells and activate...
Overview of Cell Death01:30

Overview of Cell Death

Cell death is an essential process where the body gets rid of old or damaged cells. Cell proliferation and death need to be balanced, as an imbalance between the two may lead to cancer or autoimmune diseases.
Cell death was observed in the early 19th century, but there was no experimental evidence to prove it. In 1842, Carl Vogt first discovered cell death in a metamorphic toad; however, it was not termed ‘cell death.’ Scientists discovered different cell death pathways only in the 20th century...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...